|
Apr 7
|
When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?
|
|
Mar 17
|
11 Oversold Biotech Stocks To Buy Right Now
|
|
Mar 8
|
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
|
|
Jan 5
|
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
|
|
Jan 3
|
Painful week for retail investors invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) after 5.9% drop, institutions also suffered losses
|
|
Dec 10
|
This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too
|
|
Dec 6
|
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
|
|
Dec 2
|
Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year
|
|
Nov 13
|
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
|
|
Nov 7
|
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
|
|
Nov 7
|
Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?
|
|
Nov 3
|
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
|
|
Nov 3
|
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
|
|
Nov 2
|
Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue
|
|
Nov 2
|
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
|
|
Nov 2
|
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
|
|
Aug 25
|
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
|
|
Aug 21
|
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
|
|
Jun 29
|
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
|